Aldeyra Therapeutics reports Phase 3 success with reproxalap for dry eye disease, plans third FDA filing after previous ...

Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy ...

Function Health is buying Ezra in a bid to create a haven for people who want copious amounts of data on their bodies. The ...

J&J's gene therapy bota-vec failed Phase 3 trial for X-linked retinitis pigmentosa vision loss. Follows trend of big pharma ...

Deerfield Management is back with its third healthcare venture fund, this time securing more than $600 million to create new ...

Topas Therapeutics reveals first data from celiac disease therapy study, showing promise in immune system retraining with ...

Initial clinical data from Genocury and EsoBiotec shows promise for in vivo CAR-T therapy, with complete remission in ...

Not many would argue that Biotech is one of the riskiest industries on the globe. With costs hovering in the hundreds of millions of dollars, competitors ...

While Pfizer recently pulled the plug on its most advanced obesity candidate, Amgen has moved its own key weight loss play ...

Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, ...

Kro­nos Bio, the drug de­vel­op­er long led by Gilead vet­er­an Nor­bert Bischof­berg­er, is call­ing it quits. The biotech ...

The White House’s budget request proposes a nearly $18 billion cut to NIH spending, and nearly $4 billion slashed at the CDC.